Study guide
Retinal vein and artery occlusions
European Board of Ophthalmology Diploma EBOD
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: EBOD Examination, Applications and Regulations
EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals
2 Chapter 2: Physical Optics, Photometry and Lenses
Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid
3 Chapter 3: Instrument Optics, Aberrations and Laser Physics
Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT
4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing
Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses
5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation
Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics
6 Chapter 6: Extraocular Anatomy and Motor Physiology
Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys
7 Chapter 7: Binocular Vision and Amblyopia
Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment
8 Chapter 8: Childhood Assessment and Strabismus Testing
Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts
9 Chapter 9: Esotropia, Exotropia and Vertical Deviations
Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew
10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery
Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles
11 Chapter 11: ROP and Paediatric Ocular Disease
Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding
12 Chapter 12: Ocular Surface Anatomy and Infection
Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis
13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation
Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis
14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies
Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies
15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure
Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency
16 Chapter 16: Surface Reconstruction and Keratoplasty
Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems
17 Chapter 17: Lens Development, Cataract Assessment and Biometry
Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry
18 Chapter 18: IOL Planning and Phacoemulsification
Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques
19 Chapter 19: Cataract Anaesthesia and Surgical Complications
Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO
20 Chapter 20: Corneal and Intraocular Refractive Surgery
Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange
21 Chapter 21: Presbyopia Procedures and Surface Therapeutics
Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin
22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy
Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation
23 Chapter 23: Angle, Disc and Visual-Field Assessment
Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry
24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms
Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure
25 Chapter 25: POAG, Angle Closure and Pigmentary Disease
POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma
26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment
Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers
27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion
Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions
28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy
Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis
29 Chapter 29: Inherited Retina and Electrophysiology
Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina
30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid
AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum
31 Chapter 31: Retinal Breaks and Detachment Repair
PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling
32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma
Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment
33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation
SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation
34 Chapter 34: Infectious Uveitis and Endophthalmitis
Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment
35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy
Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison
36 Chapter 36: Papilloedema, IIH and Afferent Localisation
Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization
37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology
Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies
38 Chapter 38: Central Motor Control and Cranial Nerve Palsies
Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus
39 Chapter 39: Myasthenia and Ocular Myopathy
Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome
40 Chapter 40: Pupillary Pathways and Anisocoria
Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials
41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment
Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation
42 Chapter 42: Lid Repair and Lacrimal Drainage
Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR
43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours
Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma
44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease
Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling
45 Chapter 45: Ocular Trauma and Vascular Systemic Disease
Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease
46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology
Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects
47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations
Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal
Retinal vein and artery occlusions
Key Takeaways Explain This Topic AI
RVO management addresses macular oedema, ischaemia, new vessels and systemic vascular risk.
Nonperfusion thresholds depend on imaging field; conventional disc-area criteria are not universal widefield thresholds.
Acute retinal arterial occlusion needs emergency stroke assessment, while current trials do not establish routine thrombolysis as proven visual treatment.
Last updated: October 2026
Central Retinal Vein Occlusion (CRVO)
Central retinal vein occlusion is the second most prevalent vision-threatening retinal vascular pathology worldwide, trailing only diabetic retinopathy. CRVO characteristically impacts older adults in their sixth to eighth decades, driven by systemic cardiovascular risk factors and localized anatomical vulnerabilities.
Pathogenesis: Virchow's Triad at the Lamina Cribrosa
The pathogenesis of CRVO is governed by the principles of Virchow's Triad (haemodynamic stasis, endothelial injury, and hypercoagulability) acting at a unique anatomical bottleneck:
Anatomical Confinement: The central retinal artery and central retinal vein pass together through a narrow, rigid aperture within the fibrous ring of the lamina cribrosa of the sclera, where they share a common adventitial connective tissue sheath.
Mechanical Compression & Stasis: In individuals with systemic hypertension or arteriosclerosis, atheromatous thickening and sclerosis of the relatively thick-walled central retinal artery compresses the thin-walled, compliant central retinal vein against the unyielding scleral rim of the lamina cribrosa. This compression causes luminal stenosis, creating turbulent blood flow, localized haemodynamic stasis, and secondary endothelial shear damage.
Thrombus Formation: Endothelial denudation exposes subendothelial collagen, triggering platelet aggregation, tissue factor release, and secondary intraluminal thrombus formation, totally or sub-totally occluding venous outflow.
Non-Ischaemic vs. Ischaemic CRVO
CRVO manifests as a clinical spectrum divided into two distinct functional and prognostic entities:
- Clinical & Diagnostic Parameter Non-Ischaemic CRVO (Perfused) Ischaemic CRVO (Non-Perfused)
- Frequency More common presentation Less common, but identification is essential because of neovascular risk
Presenting Visual Acuity Variable; typically better than 6 / 60 6/60 6/60 ( 20 / 200 20/200 20/200 ) Catastrophic; profound reduction, typically < 6 / 60 <6/60 < 6/60 (CF or HM)
Afferent pupillary defect Often absent or less marked A substantial RAPD supports severe asymmetric retinal ischaemia; account for fellow-eye disease
Funduscopic Appearance Mild disc oedema, scattered flame and blot haemorrhages in 4 quadrants, moderate venous engorgement Severe disc swelling, profound venous tortuosity and engorgement, confluent haemorrhages across all 4 quadrants ( "blood and thunder" fundus ), extensive cotton-wool spots
Fluorescein Angiography < 10 <10 < 10 disc areas of capillary non-perfusion ≥ 10 \ge 10 ≥ 10 disc areas of capillary non-perfusion on conventional seven-field FA; widefield thresholds require separate interpretation
Visual Field Testing Mild peripheral constriction or relative central scotoma Dense absolute scotomas; severe peripheral constriction
Neovascular complications Lower risk; reassess if perfusion worsens Greater risk of iris/angle neovascularisation and neovascular glaucoma
Evolution Can become ischaemic, so follow-up still matters Prognosis and complications depend on ischaemia, oedema and treatment
Warning
The "100-Day Glaucoma" Phenomenon: In ischaemic CRVO, widespread retinal non-perfusion triggers massive intraocular VEGF synthesis. Diffusing into the anterior chamber, VEGF stimulates neovascularisation of the iris (NVI / rubeosis iridis) and neovascularisation of the iridocorneal angle (NVA). Myofibroblastic contraction of fibrovascular membranes unzips the angle, causing peripheral anterior synechiae (PAS), intractable secondary angle closure, and disastrous intraocular pressure elevations: Neovascular Glaucoma (NVG) . The historical term "100-day glaucoma" highlights early risk, not a deadline. Neovascularisation can occur outside that interval, and anti-VEGF treatment may delay its appearance without eliminating ischaemic drive.
Systemic Evaluation in CRVO
Review blood pressure, glucose, lipid and cardiovascular risk, smoking, medications and glaucoma. History and examination may suggest a hyperviscosity, inflammatory or haematological disorder requiring targeted assessment. A young age or bilateral disease can justify further investigation, but routine inherited-thrombophilia or MTHFR panels are not indicated for every young patient. Tests should change management and be coordinated with the appropriate physician. Anticoagulation is not routine treatment for the ocular oedema of RVO.
- Evidence-Based Management of CRVO
- 1. Intravitreal Anti-VEGF Pharmacotherapy
Intravitreal anti-VEGF represents the first-line standard of care for macular oedema secondary to CRVO:
CRUISE Trial (Ranibizumab): Evaluated monthly ranibizumab (0.3 mg and 0.5 mg) vs. sham injection. At 6 months, patients receiving ranibizumab 0.5 mg gained a mean of +14.9 letters (compared to +0.8 letters with sham), with 47.7% gaining ≥ 15 \ge 15 ≥ 15 letters.
COPERNICUS and GALILEO Trials (Aflibercept): Evaluated monthly intravitreal aflibercept 2.0 mg vs. sham. At 24 weeks, aflibercept-treated eyes achieved extraordinary visual improvements of +17.3 to +18.0 letters , with over 56% to 60% gaining ≥ 15 \ge 15 ≥ 15 letters .
2. Intravitreal Corticosteroids
GENEVA Trial (Dexamethasone 0.7 mg Implant): Demonstrated that a single biodegradable dexamethasone implant (Ozurdex) produced rapid, statistically significant visual gains ( ≥ 15 \ge 15 ≥ 15 letters in ~30% of eyes at day 60). It serves as an outstanding second-line agent or primary choice in pseudophakic patients, vitrectomised eyes, or individuals unable to maintain monthly anti-VEGF injection schedules.
3. The Role of Panretinal Photocoagulation (CVOS Findings)
The landmark Central Vein Occlusion Study (CVOS) tested whether prophylactic panretinal photocoagulation (PRP) in ischaemic CRVO could prevent neovascular glaucoma:
Important
The CVOS Paradox and Modern Protocol: CVOS supported close surveillance and prompt PRP when iris/angle neovascularisation develops, rather than routine prophylactic PRP in every ischaemic CRVO. Monitor frequently during the high-risk early period and after anti-VEGF cessation. Preventive PRP may be considered when dependable surveillance is impossible, with individual discussion of harms and benefits.
Branch Retinal Vein Occlusion (BRVO)
Branch retinal vein occlusion is approximately three times more common than CRVO, typically presenting with acute, painless, sectoral visual field loss or blur.
Anatomical Predilection and Arteriovenous Crossings
BRVO often arises at an arteriovenous crossing where the artery lies anterior to the vein and shared adventitial tissue can contribute to venous compression. This disease-associated arrangement does not mean arteries are anterior at more than 99% of all normal crossings.
Mechanical Constriction: Arteriolosclerosis and chronic hypertensive thickening of the rigid arteriolar wall compress the underlying, thin-walled compliant venule against the deep retinal tissue.
Superotemporal predilection: BRVO commonly involves the superotemporal arcade, reflecting the distribution of vulnerable arteriovenous crossings; location alone does not establish perfusion or visual prognosis.
Fundus Appearance: A sharply demarcated, wedge-shaped or fan-shaped distribution of flame and blot intraretinal haemorrhages, retinal oedema, and cotton-wool spots extending outward from the offending A/V crossing point, with its apex pointing toward the blockage.
Complications and Landmark Trials in BRVO
Macular oedema: A major cause of sustained central loss. BRAVO compared ranibizumab with sham, whereas VIBRANT compared aflibercept with grid laser. Anti-VEGF is commonly a first-line option; choice incorporates anatomy, lens, pressure, contraindications and visit burden rather than a claim that both trials used a laser comparator.
Retinal neovascularisation: Ischaemic retina increases risk. Look for retinal/disc new vessels and vitreous haemorrhage; nonperfusion alone does not automatically require sector laser.
BVOS Trial (Branch Vein Occlusion Study): Demonstrated that sectoral scatter argon laser photocoagulation applied to the non-perfused retinal quadrant halved the risk of vitreous haemorrhage (reducing haemorrhage rates from 60% down to 30%) in eyes that developed retinal neovascularisation.
Central Retinal Artery Occlusion (CRAO)
CRAO causes sudden usually painless monocular loss from inner-retinal ischaemia. A relative afferent defect, retinal whitening, segmented vessels and a cherry-red fovea support the diagnosis, but may be absent early or vary with incomplete occlusion and cilioretinal supply. The thin foveola lacks the thick inner layers that whiten elsewhere, allowing the underlying choroidal colour to remain visible. A cherry-red spot is not exclusive to CRAO.
Treat suspected acute retinal arterial occlusion as a stroke emergency. Establish symptom onset/last-known-well, activate the local emergency stroke pathway and assess vascular risk and neurological symptoms. In older patients consider giant-cell arteritis: obtain urgent inflammatory markers and treat immediately when clinically suspected, without delaying for confirmation. BRAO can preserve central acuity yet still require stroke assessment. Ocular ischaemic syndrome suggests severe carotid disease and can cause mid-peripheral haemorrhages, anterior ischaemia and delayed choroidal filling; it needs vascular evaluation as well as ocular care.
Ocular massage, anterior-chamber paracentesis and other traditional pressure manipulations have no established visual benefit and can cause harm. Animal ischaemia times are not a precise human deadline for irreversible loss.
Earlier statements about thrombolysis require the current trials. THEIA (2025) did not demonstrate a significant primary visual benefit of alteplase versus aspirin in its limited sample. TenCRAOS (2026) found no significantly better recovery with tenecteplase within 4.5 hours and reported serious safety concerns, including fatal intracranial haemorrhage. This does not support routine thrombolysis as proven ophthalmic treatment. Urgent assessment remains necessary for stroke diagnosis, prevention and any locally approved trial pathway. See THEIA and TenCRAOS .
After the acute event, address cardiovascular secondary prevention through the stroke team, monitor ocular neovascularisation in high-risk eyes and provide visual rehabilitation. Explain prognosis without promising recovery from a particular rescue manoeuvre.
Laser and Imaging Decisions
For BRVO, sector laser treats retinal or disc neovascularisation rather than nonperfusion exceeding five disc areas alone. For CRVO, conventional seven-field and ultra-widefield nonperfusion measures are not interchangeable. Monitor iris and angle before dilation when appropriate and remain vigilant after stopping anti-VEGF. Apply PRP for new vessels, with preventive treatment considered individually when reliable follow-up is impossible. Anti-VEGF primarily treats macular oedema and can suppress or delay visible new vessels without eliminating ischaemia.